Solenis, which makes speciality chemicals for water-intensive industries, has made two acquisitions in the space of three days: Lilleborg, a Norwegian firm that supplies professional cleaning products, and Aqua ChemPacs, a Pennsylvania-based maker of concentrated liquid chemical packs. Terms were not disclosed in either deal.
Solugen has secured a conditional commitment for a $213.6 million loan guarantee from the US Department of Energy (DOE) Loan Programmes Office. This will be used to support the construction of the company’s Bioforge Marshall facility in Marshall, Minnesota, on which it broke ground in April.
Graham Meller of Buttonwood Marketing shares some results from a recent trial of continuous metals monitoring technology
Elementis has announced some promising results from a trial of a new continuous metals monitoring technology at a river by its talc plant at Sotkamo in central Finland. The technology employs micro-discharge optical emission spectroscopy (µDOES*) from Finnish university spin-off Sensmet.
Swiss CDMO Siegfried has signed binding agreements with Curia Global for the acquisition of a drug substances site in Grafton, Wisconsin. The deal is expected to close by 1 July, subject to customary closing conditions. No financial details are being disclosed, other than that the acquisition is being financed from existing funds and will not change the company’s outlook for 2024 and mid-term financial targets.
Luxembourg-based OCSiAl has completed construction of a 3,000 tonnes/year facility for water-based single-wall carbon nanotube (SWCNT) dispersions in Serbia to support the manufacture of high-performance batteries. It is due to begin production in Q3.
Featuring cleanroom-operated production lines, this facility is an optimised version of the previous generation, with 15 times higher output. Much of the output is contracted with global electric vehicle producers and collaborations with the world’s largest lithium-ion battery cell manufacturers, the company said.
American start-up DMC Biotechnologies, which develops and produces chemicals and ingredients using precision fermentation, has agreed to create the ‘Biotech Open Platform’ in partnership with French industrial giants Danone and Michelin, and the investment bank Crédit Agricole. The first-phase investment is over €16 million.
The European Commission has approved the first Important Project of Common European Interest (IPCEI). Under IPCEI Med4Cure, member states will provide up to €1 billion in public funding, which is expected to unlock €5.9 billion more in private funding.
